Month: March 2022

SHANGHAI, China, March 03, 2022 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Highlights:Total net revenues reached RMB5,780.8 million (US$907.1 million), a 51% increase from the same period in 2020. Average monthly active users (MAUs) reached 271.7 million, and mobile MAUs reached 252.4 million, representing increases of 35% and 35%, respectively, from the same period in 2020. Average daily active users (DAUs) reached 72.2 million, a 34% increase from the same period in 2020. Average monthly paying users (MPUs1) reached 24.5 million, a 37% increase from the same period in...

Statkraft Fredrik Åkerlund Fredrik Åkerlund, Senior Originator & Office Manager Finland(Oslo/Espoo, March 3, 2022) Today, Statkraft opens its office in Espoo, Finland. The office will focus on origination activities, providing upstream and downstream power purchase agreements (PPAs) towards industrial companies and wind power developers, investors, and operators. The new office makes Finland the 19th country with Statkraft presence on the ground. “Statkraft has been active in the Finnish market for many years from our offices in Norway. Now we are reinforcing our presence with an office in Espoo”, says Einar Hoffart, Vice President Nordic Origination in Statkraft. Last year, Statkraft closed upstream PPAs with Neste, Kemira and Keva as well as a downstream PPA with Aquila Capital. The new Espoo office will be headed by Fredrik...

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeCIP Merchant Capital Limited(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Financial Advisor to Corporation Financiere Europeenne S.A. (CFE)(d)        Date dealing undertaken:2nd March 2022(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

Bjørn Taale Sandberg Bjørn Taale Sandberg, 57 has been named DNA Plc’s Chief Strategy Officer (CSO) and a member of the Executive Team. He will start in his new position on 1 April 2022.DNA PLC STOCK EXCHANGE RELEASE 3 MARCH 2022, 11:00 EET Bjørn Taale Sandberg, 57 has been named DNA Plc’s Chief Strategy Officer (CSO) and a member of the Executive Team. He will start in his new position on 1 April 2022. Sandberg is taking up the post after acting as the SVP, Head of Research of DNA’s parent company Telenor ASA. Sandberg holds master’s degrees in Computer Science and Management. Sandberg has been with Telenor since 2000 and has held senior director positions in the Group and other Telenor operating companies. In his new role, Sandberg will work closely with DNA’s CEO and as an internal key advisor to the Executive Team. The key role...

Company announcement – No. 6 / 2022 Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021 Copenhagen, DK and Boston, MA, U.S. March 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on March 10, 2022 at 4 pm CET (10 am ET) following the announcement of results for the full year of 2021. Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, President of Zealand Pharma U.S. Frank Sanders, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President and Chief Medical Officer Adam Steensberg. The presentation will be followed by a Q&A...

Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced an update to the Financial Calendar for 2022. The planned date of the Annual General Meeting is changed to April 29, 2022, and the publication of the Annual Report for 2021 is changed to April 7, 2022. Orphazyme has thus scheduled the following dates for the remainder of 2022: Deadline for submission of shareholder proposals to Annual General MeetingMarch 17, 2022 Annual Report 2021April 7, 2022 Annual General Meeting 2022April 29, 2022 Interim Report First Half 2022August 25, 2022For additional information, please contact Orphazyme A/S Anders Vadsholt, Chief Executive Officer and Chief...